Epratuzumab

From Wikipedia, the free encyclopedia
Epratuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD22
Clinical data
Legal status ?
Identifiers
CAS number 205923-57-5 N
ATC code None
UNII 3062P60MH9 YesY
KEGG D04036 YesY
Chemical data
Formula ?
 N (what is this?)  (verify)

Epratuzumab is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE).[1][2] The manufacturers in August 2009 announced success in early trials against SLE.[3]

Mechanism

Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.

See also

External links

  1. ↑ Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
  2. ↑ Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
  3. ↑ Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
Monoclonal antibodies for the immune system
Immune system ("-l(i[m])-")
Human ("-limu-")
Mouse ("-limo-")
Chimeric ("-lixi-")
Humanized ("-lizu-")
Chimeric + humanized
("-lixizu-")
Interleukin ("-k(i[n])-")
Human ("-kinu-")
Humanized ("-kizu-", "-kinzu-")
Inflammatory lesions ("-les-")
Mouse ("-leso-")

M: LMC

cell/phys/auag/auab/comp, igrc

imdf/ipig/hyps/tumr

proc, drug (L3/4)


This article is issued from Wikipedia. The text is available under the Creative Commons Attribution/Share Alike; additional terms may apply for the media files.